Table 1.
Characteristics of older stage II or III colorectal cancer patients by chemotherapy treatment group*
| Patients receiving chemotherapy treatment |
||||||
|---|---|---|---|---|---|---|
| Patient and geographic characteristics | All stage II and III colorectal cancer patients |
without oxaliplatin† |
with oxaliplatin |
|||
| n=4,388 | col % | n=2,145 | row % | n=2,243 | row % | |
| Demographic characteristics | ||||||
| Gender | ||||||
| Male | 2,087 | 48 | 1,026 | 49 | 1061 | 51 |
| Female | 2,301 | 52 | 1,119 | 49 | 1,182 | 51 |
| Age at diagnosis (mean, SD) | 73.7 (5.3) | 74.8 (5.6) | 72.6 (4.8) | |||
| 65 – 69 | 1,199 | 27 | 456 | 38 | 743 | 62 |
| 70 – 74 | 1,360 | 31 | 624 | 46 | 736 | 54 |
| 75 – 79 | 1,144 | 26 | 584 | 51 | 560 | 49 |
| 80 – 84 | 563 | 13 | 375 | 67 | 188 | 33 |
| 85+ | 122 | 3 | 106 | 87 | 16 | 13 |
| Race | ||||||
| White Non-Hispanic | 3,551 | 81 | 1,723 | 49 | 1,828 | 51 |
| Black Non-Hispanic | 273 | 6 | 141 | 52 | 132 | 48 |
| Hispanic | 285 | 6 | 153 | 54 | 132 | 46 |
| Other Non-Hispanic | 271 | 6 | 126 | 46 | 145 | 54 |
| Unknown | 8 | 0 | 2 | 25 | 6 | 75 |
| Marital status | ||||||
| Married | 2,663 | 61 | 1,238 | 46 | 1,425 | 54 |
| Single | 291 | 7 | 136 | 47 | 155 | 53 |
| Separated, widowed, or divorced | 1,288 | 29 | 705 | 55 | 583 | 45 |
| Unknown | 146 | 3 | 66 | 45 | 80 | 55 |
| Percentage living below poverty level‡ | ||||||
| ≤ 4% | 1,052 | 24 | 476 | 45 | 576 | 55 |
| 4–8% | 1,250 | 28 | 579 | 46 | 671 | 54 |
| 8–15% | 1,031 | 23 | 531 | 52 | 500 | 48 |
| >15% | 1,055 | 24 | 559 | 53 | 496 | 47 |
| Year of diagnosis | ||||||
| 2004 | 1,283 | 29 | 926 | 72 | 357 | 28 |
| 2005 | 1,157 | 26 | 567 | 49 | 590 | 51 |
| 2006 | 987 | 22 | 361 | 37 | 626 | 63 |
| 2007 | 961 | 22 | 291 | 30 | 670 | 70 |
| Charlson Comorbidity Index | ||||||
| 0 | 2,982 | 68 | 1407 | 47 | 1575 | 53 |
| 1 | 1,029 | 23 | 534 | 52 | 495 | 48 |
| 2+ | 377 | 9 | 204 | 54 | 173 | 46 |
| Tumor characteristics at diagnosis | ||||||
| Cancer site | ||||||
| Colon | 3,745 | 85 | 1,799 | 48 | 1,946 | 52 |
| Rectum | 643 | 15 | 346 | 54 | 297 | 46 |
| AJCC/Derived AJCC stage | ||||||
| II | 1,123 | 26 | 713 | 63 | 410 | 37 |
| III | 3,265 | 74 | 1,432 | 44 | 1,833 | 56 |
| Geographic characteristics | ||||||
| County of residence size (metro area)‡ | ||||||
| Metropolitan | 3,685 | 84 | 1,765 | 48 | 1,920 | 52 |
| Non-metropolitan | 703 | 16 | 380 | 54 | 323 | 46 |
| Region | ||||||
| Northeast | 1,045 | 24 | 544 | 52 | 501 | 48 |
| South | 873 | 20 | 441 | 51 | 432 | 49 |
| Midwest | 716 | 16 | 389 | 54 | 327 | 46 |
| West | 1,754 | 40 | 771 | 44 | 983 | 56 |
*
Cases obtained from the Surveillance, Epidemiology and End Results Program 17 registries were included in this analysis.
†
94% of the individuals who received treatment without oxaliplatin (n=2,473) received 5-FU or capecitabine alone. All remaining individuals (n=163) received another combination of chemotherapy agents.
‡
Percentage of census tract living below the poverty line and county of residence in metro area size are linked from 2000 Census data.